The drugstore chain also aims to lower capital expenditures by about $600 million, and expects to see the impact of the cost reductions begin by early next year, according to a statement Thursday. The plans set the stage for the arrival of new CEO Tim Wentworth, who’s scheduled to take over on Oct. 23.